Beam Therapeutics
(NASDAQ:BEAM)
$23.90
-0.41[-1.69%]
At close: Apr 19
$23.90
0[0.00%]
After Hours: 4:00PM EDT
Consensus Rating1
Outperform
Highest Price Target1
$149.00
Lowest Price Target1
$30.00
Consensus Price Target1
$61.56

Beam Therapeutics Stock (NASDAQ:BEAM), Analyst Ratings, Price Targets, Predictions

Beam Therapeutics Inc has a consensus price target of $61.56, established from looking at the 36 latest analyst ratings. The last 3 analyst ratings were released from BMO Capital, Barclays, and RBC Capital on March 27, 2024, February 28, 2024, and February 28, 2024. With an average price target of $44.67 between BMO Capital, Barclays, and RBC Capital, there's an implied 86.89% upside for Beam Therapeutics Inc from these 3 analyst ratings.

Analyst Trend
1
Dec 23
1
Jan
1
Feb
1
Mar
Buy
Hold
Sell
Strong Sell
Analyst Rating
12345
3.3
Hold
Strong Buy
Buy
Hold
Sell
Strong Sell

Analyst Firms Making Recommendations1

BMO Capital
Barclays
RBC Capital
JP Morgan
B of A Securities

1calculated from analyst ratings published within the last 3 years

Analyst Ratings for Beam Therapeutics

date
ticker
Buy Now
Company
Current price
Upside/Downside
Analyst Firm
Analyst & % Accurate
Price Target Change
Rating Change
Previous / Current Rating
Get Alert
03/27/2024BEAMBuy Now
Beam Therapeutics
$23.90138.49%BMO Capital
Kostas Biliouris
→ $57MaintainsOutperformGet Alert
02/28/2024BEAMBuy Now
Beam Therapeutics
$23.9075.73%Barclays
Gena Wang
$26 → $42MaintainsEqual-WeightGet Alert
02/28/2024BEAMBuy Now
Beam Therapeutics
$23.9046.44%RBC Capital
Luca Issi
$27 → $35MaintainsSector PerformGet Alert
01/29/2024BEAMBuy Now
Beam Therapeutics
$23.9067.36%JP Morgan
Eric Joseph
$38 → $40UpgradeNeutral → OverweightGet Alert
12/15/2023BEAMBuy Now
Beam Therapeutics
$23.9046.44%B of A Securities
Greg Harrison
→ $35DowngradeBuy → NeutralGet Alert
12/08/2023BEAMBuy Now
Beam Therapeutics
$23.9025.52%Jefferies
Michael Yee
$75 → $30DowngradeBuy → HoldGet Alert
10/17/2023BEAMBuy Now
Beam Therapeutics
$23.9033.89%Cantor Fitzgerald
Rick Bienkowski
$56 → $32MaintainsOverweightGet Alert
09/13/2023BEAMBuy Now
Beam Therapeutics
$23.90134.31%Cantor Fitzgerald
Rick Bienkowski
→ $56ReiteratesOverweight → OverweightGet Alert
08/29/2023BEAMBuy Now
Beam Therapeutics
$23.90134.31%Cantor Fitzgerald
Rick Bienkowski
→ $56ReiteratesOverweight → OverweightGet Alert
08/09/2023BEAMBuy Now
Beam Therapeutics
$23.9046.44%Barclays
Gena Wang
$41 → $35MaintainsEqual-WeightGet Alert
08/09/2023BEAMBuy Now
Beam Therapeutics
$23.9096.65%Credit Suisse
Richard Law
$46 → $47MaintainsNeutralGet Alert
08/09/2023BEAMBuy Now
Beam Therapeutics
$23.90134.31%Citigroup
Samantha Semenkow
$60 → $56MaintainsBuyGet Alert
05/11/2023BEAMBuy Now
Beam Therapeutics
$23.9075.73%RBC Capital
Luca Issi
$50 → $42MaintainsSector PerformGet Alert
05/11/2023BEAMBuy Now
Beam Therapeutics
$23.9071.55%Barclays
Gena Wang
$45 → $41MaintainsEqual-WeightGet Alert
05/11/2023BEAMBuy Now
Beam Therapeutics
$23.90151.05%Citigroup
Samantha Semenkow
$62 → $60MaintainsBuyGet Alert
03/21/2023BEAMBuy Now
Beam Therapeutics
$23.9054.81%Bernstein
William Pickering
→ $37Initiates → Market PerformGet Alert
03/01/2023BEAMBuy Now
Beam Therapeutics
$23.90339.33%Wells Fargo
Yanan Zhu
$125 → $105MaintainsOverweightGet Alert
02/01/2023BEAMBuy Now
Beam Therapeutics
$23.90159.41%Cantor Fitzgerald
Rick Bienkowski
→ $62Initiates → OverweightGet Alert
01/23/2023BEAMBuy Now
Beam Therapeutics
$23.90222.18%SVB Leerink
Mani Foroohar
$81 → $77MaintainsOutperformGet Alert

FAQ

Q

What is the target price for Beam Therapeutics (BEAM)?

A

The latest price target for Beam Therapeutics (NASDAQ: BEAM) was reported by BMO Capital on March 27, 2024. The analyst firm set a price target for $57.00 expecting BEAM to rise to within 12 months (a possible 138.49% upside). 15 analyst firms have reported ratings in the last year.

Q

What is the most recent analyst rating for Beam Therapeutics (BEAM)?

A

The latest analyst rating for Beam Therapeutics (NASDAQ: BEAM) was provided by BMO Capital, and Beam Therapeutics maintained their outperform rating.

Q

When was the last upgrade for Beam Therapeutics (BEAM)?

A

The last upgrade for Beam Therapeutics Inc happened on January 29, 2024 when JP Morgan raised their price target to $40. JP Morgan previously had a neutral for Beam Therapeutics Inc.

Q

When was the last downgrade for Beam Therapeutics (BEAM)?

A

The last downgrade for Beam Therapeutics Inc happened on December 15, 2023 when B of A Securities changed their price target from N/A to $35 for Beam Therapeutics Inc.

Q

When is the next analyst rating going to be posted or updated for Beam Therapeutics (BEAM)?

A

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Beam Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Beam Therapeutics was filed on March 27, 2024 so you should expect the next rating to be made available sometime around March 27, 2025.

Q

Is the Analyst Rating Beam Therapeutics (BEAM) correct?

A

While ratings are subjective and will change, the latest Beam Therapeutics (BEAM) rating was a maintained with a price target of $0.00 to $57.00. The current price Beam Therapeutics (BEAM) is trading at is $23.90, which is within the analyst’s predicted range.

Browse analyst ratings and price targets on all stocks.

People Also Watch